Sandoz submits ANDA for Tivozanib, marking a new generic entry
Sandoz Inc. has submitted an Abbreviated New Drug Application (ANDA) for Tivozanib.
Published: July 17, 2026
Updated: July 17, 2026
Author: Humanexa Intelligence
Therapeutic area: Oncology / VEGF Inhibitor
Company: Sandoz
Asset: Tivozanib
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Sandoz
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The submission of an ANDA for Tivozanib by Sandoz introduces a new generic competitor, which could significantly alter market dynamics and pricing strategies. Portfolio teams must evaluate the potential impact on market share for existing Tivozanib products and adjust strategies accordingly.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the FDA's review timeline and any subsequent approvals or market entries by competitors.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.